CHARGED PHOSPHOLIPID COMPOSITIONS AND METHODS FOR THEIR USE

• US 20080275007A1
• Filed: 04/21/2008
• Published: 11/06/2008
• Est. Priority Date: 07/31/2000
• Status: Abandoned Application

• Current Assignee: Cerenis Therapeutics Holding SA
• Original Assignee: Cerenis Therapeutics Holding SA
• Inventors: Sparks, Daniel L.
• Application Number:
  US12/106,848
• Publication Number:
  US 20080275007A1
• Time in Patent Office: Days
• US Class Current: 514/114
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/66 Phosphorus compounds
• CPC Class Codes: A61K 31/663 Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• CPC Class Codes: A61K 31/683 Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
• CPC Class Codes: A61K 31/685 one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 39/02 Antidotes
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins.

Claims

1. A method for clearing a virus or a bacterial endotoxin from the bloodstream of a mammal infected with the virus or a bacterium, the method consisting essentially of administering to said mammal a therapeutically effective amount of a negatively charged phospholipid for achieving removal of said virus or said endotoxin from the bloodstream of said mammal.

2. The method of claim 1, wherein the mammal is a human.

3. The method of claim 1, wherein said negatively charged phospholipid is phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, or phosphatidic acid, or any combination thereof.

4. The method of claim 1, wherein said negatively charged phospholipid is phosphatidylinositol.

5. The method of claim 1, wherein said negatively charged phospholipid is phosphatidylserine.

6. The method of claim 1, wherein said negatively charged phospholipid is phosphatidylglycerol.

7. The method of claim 1, wherein said negatively charged phospholipid is phosphatidic acid.

8. The method of claim 1, wherein said negatively charged phospholipid is administered in a dose of 5 micromole to 100 micromole per kg body weight of the mammal.

9. The method of claim 1, wherein said negatively charged phospholipid is administered in a dose of 5 micromole to 20 micromole per kg body weight of the mammal.

10. The method of claim 1, wherein said negatively charged phospholipid is formulated as a food additive.

11. The method of claim 1, wherein said negatively charged phospholipid is formulated as a medicament.

12. The method of claim 11, wherein the medicament is administered orally, intranasally, transdermally, or by injection.

13. The method of claim 1, wherein said negatively charged phospholipid is in the form of unilammellar vesicles, multilamellar vesicles, multilamellar sheets, dispersion, micellar solutions, emulsions, or microemulsions.

14. The method of claim 1, wherein said negatively charged phospholipid is in the form of a powder.

16. The method of claim 1, wherein said virus belongs to the Herpes virus family.

17. The method of claim 16, wherein said virus is cytomegalovirus (CMV).

15. (canceled)

18-20. -20. (canceled)